ove patient healthcare, shorten treatments, and reduce expense," says Alice Jacobs, MD, Chairman & CEO of IMDx. "This agreement, which demonstrates Abbott Molecular's commitment to menu expansion on the m2000 system, will allow customers to gain access to a broad menu of FDA and internationally marketed assays, th

ove patient healthcare, shorten treatments, and reduce expense," says Alice Jacobs. MD, Chairman & CEO of IMDx. "This agreement, which demonstrates Abbott Molecular's commitment to menu expansion on the m2000 system, will allow customers to gain access to a broad menu of FDA and internationally marketed assays, t